NCT07140315招募中1 期
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2026年9月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Safety of [18F]DK222 as assessed by number of grade 3-5 adverse events
研究概览
简要总结
This Phase 1 clinical trial will test a new drug called [18F]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. [18F]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system.
This is a first in human study to collect preliminary safety and toxicity data of [18F]DK222.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must sign informed consent prior to inclusion in this trial.
- •Subjects must be ≥18 years of age and competent to give informed consent.
- •Subjects must be diagnosed with histologically confirmed NSCLC or UC and eligible for anti-PD(L)-1 therapy.
- •PD-L1 immunohistochemistry result using a Clinical Laboratory Improvement Amendments (CLIA) assay must be available or if not available then sufficient tissue must be available to perform PD-L1 testing.
- •Subjects must score at least 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
- •Subjects must have adequate organ function as defined by the following laboratory values (determined within 28 days prior to randomization/registration) or as deemed not clinically significant by physician on record:
- •White blood cells (WBC) ≥ 2000 /μL
- •Absolute neutrophil count (ANC) ≥ 1500 /μL
- •Platelets ≥ 100 x103 /μL
- •Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
- •Serum creatinine ≤ 1.5 times upper limit of normal (ULN) or creatinine clearance greater than or equal to 60 ml/min (using the Cockcroft-Gault formula)
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN
- •Bilirubin ≤ 1.5 times ULN (Except patients with the Gilbert Syndrome, for whom a maximum of ≤ 3.0 mg/dL is acceptable)
- •Women of childbearing potential (WOCBP) should have a negative serum pregnancy test within 24 hours prior to receiving the first administration [18F]DK
- •Women with non-childbearing potential may be included if either surgically sterile or have been postmenopausal for ≥ 1 year.
- •WOCBP and men who are sexually active with WOCBP must agree to use appropriate method(s) of contraception.
排除标准
- •Prior treatment, in either de novo disease or during this recurrence, with an anti-PD-L1 or anti-PD-L2 antibody. A minimum of 4 month washout period is required for patients treated with anti-PD-L1 or anti-PD-L2 therapy. Patients with disease that was previously treated with anti-PD-1, anti-PD-L1, anti-PD-L2 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, but now have a new recurrence, would be eligible.
- •Subjects who have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1 or better from the adverse events due to previous cancer therapy.
- •Treatment with corticosteroids in an increasing dosage in the 7 days prior to the first administration of anti-PD
- •(A stable or decreasing dosage of ≤ 10 mg dexamethasone or equivalent is allowed. In addition, inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.)
- •A severe hypersensitivity reaction to prior treatment with a monoclonal antibody, or known hypersensitivity to study drugs components.
- •Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patients to receive protocol therapy.
- •Women of childbearing potential with a positive serum or urine pregnancy test (minimum sensitivity 10 IU/L or equivalent units of HCG) within 24 hours prior to the start of imaging.
- •Breastfeeding women.
- •Inability to comply with other requirements of the protocol.
研究组 & 干预措施
[18F]DK222 radiotracer
Experimental
The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of [18F]DK222 radiotracer in NSCLC and UC participants. Participants will undergo a PET-CT scan after [18F]DK222 is injected into the participant's vein an intravenous line. This is the imaging procedure to assess where [18F]DK222 has accumulated in the body.
干预措施: [18F]DK222 radiotracer (Drug)
结局指标
主要结局
Safety of [18F]DK222 as assessed by number of grade 3-5 adverse events
时间窗: Once up to 10 days post radiotracer injection
Any grade 3-5 toxicity attributed to \[¹⁸F\]DK222 administration will be considered as not meeting the safety endpoint. All adverse events (AEs) will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
次要结局
- Tolerability of [18F]DK222 as assessed by number of grade 3-5 adverse events(Once up to 10 days post radiotracer injection)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal CancerColon Cancer Liver MetastasisNCT03370198Celyad Oncology SA1
Unknown
1 期
Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer PatientsProstate CancerNCT00895466Pepscan Therapeutics12
已完成
1 期
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including LymphomasSolid TumorsNCT01279603Genus Oncology, LLC23
终止
1 期
Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy VolunteersAlzheimer's DiseaseNCT00777361AstraZeneca9
招募中
1 期
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal CancerHPV-Related Cervical CarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaNCT06319963Theravectys S.A.72